Regular Article
Immune Function in Patients with Rheumatoid Arthritis Treated with Etanercept

https://doi.org/10.1006/clim.2001.5183Get rights and content

Abstract

Etanercept, a recombinant human tumor necrosis factor (TNF) inhibitor that binds both soluble and cell-bound TNF, has been shown to reduce disease activity and inhibit joint destruction when administered to patients with rheumatoid arthritis (RA). Because TNF receptors are found on many types of cells that modulate the immune response, we evaluated the general immune function of a subset of RA patients in a blinded clinical study. No significant differences were seen between patients treated with etanercept or placebo in the surface antigen phenotypes of peripheral blood leukocytes, T cell proliferative responses, neutrophil function, delayed-type hypersensitivity (DTH) reactions, serum immunoglobulin levels, or incidence of infections. Although this observational study was relatively small and could detect only major changes in immunological status, the stability of immune function over time in patients receiving etanercept corroborates the findings in clinical studies, which suggest that etanercept does not alter overall global immune function.

References (35)

  • A. Lugering et al.

    Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspace-dependent pathway

    Gastroenterology

    (2001)
  • M.H. Pillinger et al.

    The neutrophil in rheumatoid arthritis

    Rheum. Dis. Clin. North Am.

    (1995)
  • R. Beyaert et al.

    Tumor necrosis factor and lymphotoxin

    Cytokines

    (1998)
  • J.J. Oppenheim et al.

    Cytokines

    Basic and Clinical Immunology

    (1991)
  • T. Saxne et al.

    Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum

    Arthritis Rheum.

    (1988)
  • C.Q. Chu et al.

    Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

    Arthritis Rheum.

    (1991)
  • K.M. Mohler et al.

    Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists

    J. Immunol.

    (1993)
  • J.M. Bathon et al.

    A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

    N. Engl. J. Med.

    (2000)
  • D.J. Lovell et al.

    Etanercept in children with polyarticular juvenile rheumatoid arthritis

    N. Engl. J. Med.

    (2000)
  • L.W. Moreland et al.

    Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

    N. Engl. J. Med.

    (1997)
  • L.W. Moreland et al.

    Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

    Ann. Intern. Med.

    (1999)
  • M.D. Weinblatt et al.

    A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

    N. Engl. J. Med.

    (1999)
  • F.C. Arnett et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

    Arthritis Rheum.

    (1988)
  • W.W. Chatham et al.

    Determinants of neutrophil HOCl generation: Ligand-dependent responses and the role of surface adhesion

    J. Leukocyte Biol.

    (1994)
  • J. Hed et al.

    Differences in the ingestion mechanisms of IgG and C3b particles in phagocytosis by neutrophils

    Immunology

    (1982)
  • E.M. Paleolog et al.

    Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis

    Arthritis Rheum.

    (1996)
  • H.-M. Lorenz et al.

    In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis

    J. Immunol.

    (1996)
  • Cited by (61)

    • miR-22 inhibits synovial fibroblasts proliferation and proinflammatory cytokine production in RASF via targeting SIRT1

      2020, Gene
      Citation Excerpt :

      Some studies have found that the pathogenesis of RA may involve local microenvironment factors, multiple gene regulation, and other random factors, but the etiology of RA has not been fully elucidated (Kurko et al., 2013). Studies have shown that the inflammatory response in patients with RA is associated with congenital and acquired immune function, and the use of anti-protein drugs has a specific therapeutic effect on patients with RA (Moreland et al., 2002; Cordain et al., 2000). Therefore, targeting inflammation in patients with RA is one of the key research directions in RA therapy.

    • Novel aspects of the activation of NADPH oxidase in neutrophils of rheumatic patients on biological therapy

      2019, International Immunopharmacology
      Citation Excerpt :

      An increased ROS formation was observed by Capsoni et al. [39] in isolated neutrophils of rheumatic patients receiving adalimumab therapy. In other studies, the biological therapy did not exert any effect [20,40,41], yet none of these investigations included a separate detection of extra- and intracellular ROS. The antibodies against TNFα or IL-6 receptor increased the intracellular but not extracellular chemiluminescence.

    • Neutrophils

      2016, Kelley and Firestein's Textbook of Rheumatology: Volumes 1-2, Tenth Edition
    View all citing articles on Scopus
    1

    To whom correspondence should be addressed, Larry W. Moreland, MD at Arthritis Clinical Intervention Program, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 17176th Ave. S, Room 068, Birmingham, AL 35294-7201. Fax: (205) 975-5554. E-mail: [email protected].

    View full text